

A20 homing (CLA⁺) and gut homing ($\alpha 4\beta 7^+$ and αE^+) CD4⁺ lymphocytes (Figures 12A-12D). Bonzo was co-expressed with CCR1, CCR2, CCR5, CCR6, CXCR1, CXCR2 or CXCR3 on lymphocytes (Figures 13A-13J).

Please replace the paragraph at page 72, lines 9 through 17 with the following paragraph:

A21 This study demonstrates that recombinant SExCkine and recombinant proteins encoding parts of the amino terminal portion of SExCkine can be used in conjunction with Bonzo (e.g., a cell expressing Bonzo) in receptor binding assays and functional assays to screen for potential agonists and antagonists of Bonzo. Considering that Bonzo is highly expressed on all classes of chronically stimulated T cell subsets, antagonists of the receptor (e.g., mAbs 4A11, 7A2 and 7F3) can be administered to treat chronic inflammatory diseases. Furthermore, agonists of Bonzo (e.g., SExCkine) can be administered to recruit killer T cell subsets to, for example, solid tumors or sites of infection.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (pages i-ix).

In the Claims

Please cancel Claims 1-15, 17-20, 48-50, 52, 54-57, 59, 61-66, 68, 70-76, 78, 79, 81-83, 85-87, 95 and 96. Claims 24, 27-33, 35, 43-46, 84 and 88 have been amended and are presented below in amended form and Claims 97-112 have been added. In accordance with 37 C.F.R. § 1.121(c)(1)(ii), amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages x-xii).

- A22 24. (Amended) The antibody or antigen-binding fragment of Claim 21 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC₅₀ of less than about 7 μ g/mL.

27. (Amended) The antibody or antigen-binding fragment of Claim 21 wherein the binding of said antibody or said antigen-binding fragment to Bonzo can be inhibited by an antibody selected from the group consisting of mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991, mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992 and mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.

A23
09940063-082701
28. (Amended) An antibody produced by murine hybridoma 4A11, deposited as ATCC Accession Number PTA-991, or an antigen-binding fragment thereof.

29. (Amended) An antibody produced by murine hybridoma 7A2, deposited as ATCC Accession Number PTA-992, or an antigen-binding fragment thereof.

30. (Amended) An antibody produced by murine hybridoma 7F3, deposited as ATCC Accession Number PTA-990, or an antigen-binding fragment thereof.

31. (Amended) Murine hybridoma 4A11, deposited as ATCC Accession Number PTA-991.

32. (Amended) Murine hybridoma 7A2, deposited as ATCC Accession Number PTA-992.

33. (Amended) Murine hybridoma 7F3, deposited as ATCC Accession Number PTA-990.

~~A24~~
35. (Amended) The isolated cell of Claim 34 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo *in vitro* assay with an IC_{50} of less than about 7 $\mu\text{g/mL}$.

A25
43. (Amended) The antibody or antigen-binding fragment of Claim 42 wherein said antibody or antigen-binding fragment thereof inhibits a cellular response in an *in vitro* assay with an IC_{50} of less than about 7 $\mu\text{g/mL}$.

44. (Amended) The antibody or antigen-binding fragment of Claim 42 wherein said cellular response is chemotaxis.

A25
45. (Amended) The antibody or antigen-binding fragment of Claim 41 wherein said mammalian Bonzo is human Bonzo.

46. (Amended) The antibody or antigen-binding fragment of Claim 41 wherein said ligand is SExCkine.

84. (Amended) A test kit for use in detecting the presence of mammalian Bonzo or portion thereof in a biological sample comprising

- A26
- a) an antibody or antigen-binding fragment thereof which binds to mammalian Bonzo and inhibits binding of a ligand to said mammalian Bonzo; and
 - b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen-binding fragment and said mammalian Bonzo.

88. (Amended) The test kit of Claim 84 wherein said antibody or antigen-binding fragment is selected from the group consisting of

- Sub B2
A27
- a) mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991;
 - b) mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992;
 - c) mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990;
 - d) an antibody which can compete with mAb 4A11, mAb 7A2 or mAb 7F3 for binding to mammalian Bonzo; and
 - e) an antigen-binding fragment of (a), (b), (c) or (d).

97. (New) The antibody or antigen-binding fragment of Claim 21 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 5 $\mu\text{g/mL}$.
98. (New) The antibody or antigen-binding fragment of Claim 21 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 1 $\mu\text{g/mL}$.
99. (New) The isolated cell of Claim 34 which produces an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 5 $\mu\text{g/mL}$.
100. (New) The isolated cell of Claim 34 which produces an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 1 $\mu\text{g/mL}$.
101. (New) The antibody or antigen-binding fragment of Claim 41 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 5 $\mu\text{g/mL}$.
102. (New) The antibody or antigen-binding fragment of Claim 41 wherein said antibody or antigen-binding fragment inhibits a cellular response to binding of ligand to said Bonzo in an *in vitro* assay with an IC_{50} of less than about 1 $\mu\text{g/mL}$.

A28

09/449,437

103. (New) The antibody or antigen-binding fragment of Claim 21 wherein said antibody or antigen-binding fragment has the epitopic specificity of an antibody selected from the group consisting of mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991; mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992; and mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.
104. (New) The antibody or antigen-binding fragment of Claim 103 wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.
105. (New) The isolated cell of Claim 34 which produces an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment has the epitopic specificity of an antibody selected from the group consisting of mAb 4A11, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-991; mAb 7A2, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-992; and mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.
106. (New) The isolated cell of Claim 105 which produces an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment has the epitopic specificity of mAb 7F3, the antibody produced by the hybridoma cell line deposited as ATCC Accession Number PTA-990.

A28
FO/280" E9004650

- ~~en-binding fra
s the epitopic s
posited as AT~~